Details for New Drug Application (NDA): 217900
✉ Email this page to a colleague
The generic ingredient in LEQSELVI is deuruxolitinib phosphate. One supplier is listed for this compound. Additional details are available on the deuruxolitinib phosphate profile page.
Summary for 217900
| Tradename: | LEQSELVI |
| Applicant: | Sun Pharm Inds Inc |
| Ingredient: | deuruxolitinib phosphate |
| Patents: | 6 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 217900
Generic Entry Date for 217900*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 217900
Suppliers and Packaging for NDA: 217900
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LEQSELVI | deuruxolitinib phosphate | TABLET;ORAL | 217900 | NDA | Sun Pharmaceutical Industries, Inc. | 47335-108 | 47335-108-86 | 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (47335-108-86) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 8MG BASE | ||||
| Approval Date: | Jul 25, 2024 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Jul 25, 2029 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | May 4, 2037 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF ADULT PATIENTS WITH ALOPECIA AREATA | ||||||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | May 21, 2041 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF ADULT PATIENTS WITH ALOPECIA AREATA | ||||||||
Complete Access Available with Subscription
